Corcept Therapeutics

ISIN US2183521028

 | 

WKN 529882

Market cap (in EUR)
5,527 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.
Show more Show less
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 5,527 m
EPS, EUR 0.30
P/B ratio 10.0
P/E ratio 170.5
Dividend yield 0.00%

Income statement (2025)

Revenue, EUR 675 m
Net income, EUR 87 m
Profit margin 12.89%

What ETF is Corcept Therapeutics in?

There are 4 ETFs which contain Corcept Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Corcept Therapeutics is the iShares S&P SmallCap 600 UCITS ETF.
ETF Weight Investment focus Fund size (in m EUR)
iShares S&P SmallCap 600 UCITS ETF 0.24%
Equity
United States
Small Cap
2,523
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
531
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.01%
Equity
North America
Social/Environmental
26
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.06%
Equity
United States
Small Cap
210
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.